Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk to expand China R&D

Novo Nordisk is to double the size of its R&D centre in China by 2015

Novo Nordisk is to double the size of its R&D centre in Beijing, China by 2015.

The diabetes specialist said the level of employees at the centre will increase from 100 to 200, with a focus on creating a new Diabetes Research Unit in the country.

 

A picture of a building housing a Diabetes Research Unit in China

Novo Nordisk R&D centre in China

 

"By doubling the current staff at our R&D centre, Novo Nordisk acknowledges the achievements of the Chinese staff since the centre was established in 1997," said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Denmark-based Novo Nordisk.

"And once again, we demonstrate our long term commitment to take part in the scientific and technological development of China, while at the same time helping Novo Nordisk to get access to the tremendous resource of talents, ideas and innovation in China."

Since its establishment, the R&D centre has focused on building expertise in protein engineering and purification, as well as creating and improving monoclonal antibodies.

The expansion will see Novo Nordisk research biopharmaceutical approaches to develop new treatments against diabetes.

The company said the R&D team in China "will eventually take part in all aspects of drug discovery, from innovation to developing drug candidates for clinical studies in humans."

14th September 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency. We dispense pioneering and creative campaigns, driven by...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics